Autopsy and confirming a diagnosis

What does a post-mortem examination still add?

Four things are named in the 2026 recommendations: confirming or excluding the diagnosis, establishing the disease subtype, obtaining tissue for PRNP genetic testing where blood was not taken in life, and providing tissue for research. A family’s own wish for certainty is treated as a fifth reason.

There are also diagnoses that CSF testing will miss. Canadian laboratory data covering 2016 to 2024 found 95 percent of 284 autopsy-confirmed cases positive by endpoint quaking-induced conversion, with one false positive among 35 confirmed non-CJD cases, and people with disease-causing PRNP mutations excluded from that analysis. A negative result in life therefore leaves a group in whom only tissue examination settles the question, and a positive result in someone with an atypical course is worth confirming.

How is an examination arranged?

The route depends on the country. In the United States the National Prion Disease Pathology Surveillance Center runs an autopsy coordination program for suspected prion disease, and states that the service and the autopsy are performed free of charge for US cases. The centre covers autopsy-related expenses including CJD testing and round-trip transport between storage and the autopsy site, and does not cover funeral or embalming charges. Families or clinicians call 216-368-0587 and ask for an autopsy coordinator, with a secure email route and an out-of-hours line. Staff confirm that prion disease is clinically suspected before agreeing to help.

Examinations are coordinated to the nearest approved regional site willing to perform them, and most states have at least one. Where no regional provider is reasonably close, a professional can be brought to the patient for brain recovery, which needs permission from an autopsy site and takes two to seven days to arrange.

In the UK, the CJD Pathology Service at the University of Edinburgh provides specialist advice and support on neuropathological enquiries related to suspected cases, with named pathology contacts. The ACDP guidance set published by the Department of Health and Social Care includes an annex for pathologists and pathology laboratories handling tissues from patients with or at risk of CJD, an annex on care after death, and an information sheet for funeral directors and relatives.

In Germany, the neuropathology institute at Saarland University Medical Centre in Homburg asks clinicians to contact it before a biopsy or autopsy is taken where prion testing is planned, and gives telephone numbers for that purpose.

Who consents, and when should the conversation happen?

In the US programme the autopsy consent form must be completed and signed by the legal next of kin as determined by local jurisdiction, with a certified or wet signature. The 2026 UK recommendations place the conversation during future care planning, alongside the other decisions families are asked to make, and not in the hours after a death.

Consent is also the point at which genetic disclosure is settled. At autopsy consent, the legal next of kin is asked whether genetic results should be disclosed, the family can defer receiving them, and the next of kin is encouraged to discuss results with at-risk first-degree relatives.

Is it brain-only, and does it delay the funeral?

Most consented examinations are limited to the brain. Sampling from a fresh brain allows the remainder to return to the body before the funeral without delay, while prolonged fixation improves diagnostic yield. The US programme aims to complete the procedure within one to three days of death, says it can be performed a few days after death without jeopardising tissue quality, and states that it usually does not delay funeral arrangements. Weekends and holidays can add a day or two. No US state is known to require an autopsy for suspected CJD, although several require reporting and strongly recommend one.

Embalming and open-casket viewing are described as medically permissible, with the individual funeral home making the final decision. Families who wish to see or touch the person should not be discouraged, preferably before the examination takes place.

What tests are run on the tissue?

Up to four different tests in the US programme, which is funded to test for prion diseases only. If CJD testing is negative, remaining tissue can be sent to a physician or medical centre for further neuropathological work-up. The German laboratory describes a membrane adsorption assay on native tissue, Western blot typing after enzyme digestion to distinguish type 1 and type 2 aggregates, and paraffin-embedded tissue blotting on decontaminated sections to show the distribution of fine deposits.

Handling reflects transmissibility. In the UK account, brain samples are handled in a containment level 3 laboratory, with derogations, until they are formalin fixed and formic acid treated, and the German laboratory decontaminates fixed tissue with formic acid before paraffin embedding to protect staff.

How long do results take, and who gets them?

Investigations can take up to three months in the UK account, and the US centre releases final reports approximately three months from the date of autopsy. The US centre releases results only to physicians: those listed on the consent packet, or the submitting physician where a sample was sent without coordination. Physicians are expected to discuss the results with the family.

Families who are weighing the decision will usually have read autopsy and brain donation first. The investigations that come before this point are covered in suspected case pathway and conditions that can look similar, and the rest of this section starts at for clinicians.